
NYSE:CVS
This summary was created by AI, based on 9 opinions in the last 12 months.
CVS Health Corp has shown positive momentum, recently beating earnings and revenue expectations, which has contributed to an 8% surge in share price, marking a three-year high. Although the stock appears cheap based on surface valuation metrics, experts caution that its low price may reflect underlying issues, such as questions around the retail pharmacy space and the impact of government regulations on their managed care business. The company is in the midst of a turnaround, bolstered by strong leadership and an impressive improvement in its health insurance sector. Analysts express mixed feelings, noting potential for upside but recommending caution until further visibility is achieved regarding its recovery. A significant percentage of analysts see potential gains towards the price target of $95.00, but there remain concerns about execution risks and the overall state of the business model.
(Market Call Minute) drugstore and a pharmacy benefit manager and they are clicking along on all cylinders.